^
Association details:
| Biomarker: | ABCC1 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | CAP-0121 (DNA damage stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5462 - BPI-361175, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC)
Published date:
03/09/2022
Excerpt:
CAP-0121 also retains activity against multidrug resistant cell lines including MRP1 and MDR1 expressing variants. As a result CAP-0121 is capable of inducing tumor remission in MDR xenograft models that are unresponsive to 35 conventional and experimental agents, and in which irofulven is only capable of slowing the rate of tumor growth.
